BACKGROUND AND PURPOSE5-HT (serotonin) regulates various physiological functions, both directly and via enteric neurons. The present study investigated the role of endogenous 5-HT and 5-HT 3 receptors in the pathogenic mechanisms involved in colonic inflammation, especially in relation to substance P (SP) and the neurokinin-1 (NK 1 ) receptor.
EXPERIMENTAL APPROACHThe effects of 5-HT 3 and NK 1 receptor antagonists were examined in dextran sulphate sodium (DSS)-induced colitis in mice. Inflammatory mediator expression and the distribution of 5-HT 3 and NK 1 receptors were also determined.
KEY RESULTSDaily administration of ramosetron and ondansetron (5-HT 3 antagonists) dose-dependently attenuated the severity of DSSinduced colitis and up-regulation of inflammatory mediator expression. Immunohistochemical analysis showed 5-HT 3 receptors are mainly expressed in vesicular ACh transporter-positive cholinergic nerve fibres in normal colon. DSS increased the number of colonic nerve fibres that were double positive for 5-HT 3 receptors and SP but not of those that were double positive for 5-HT 3 receptors and vesicular ACh transporter. DSS increased colonic SP levels and SP-positive nerve fibres; these responses were attenuated by ramosetron. DSS-induced colitis and up-regulation of inflammatory mediators were attenuated by aprepitant, an NK 1 antagonist. Immunohistochemical studies further revealed that DSS treatment markedly increased NK 1 receptor expression in CD11b-positive cells.
CONCLUSIONS AND IMPLICATIONSThese findings indicate that the 5-HT/5-HT 3 receptor and SP/NK 1 receptor pathways play pathogenic roles in colonic inflammation. 5-HT acts via 5-HT 3 receptors to up-regulate inflammatory mediators and promote colonic inflammation. These effects may be further mediated by activation of macrophage NK 1 receptors via SP released from 5-HT 3 receptor-positive nerve fibres. The 5-HT 3 receptor is a ligand-gated cation channel and is widely distributed in brain and spinal cord neurones, as well as in the gastrointestinal tract (Farber et al., 2004). In the gastrointestinal tract, the 5-HT 3 receptor is involved in secretory, peristaltic, emetic and pain responses (Siriwardena et al., 1993;Jackson and Yakel, 1995;Hansen, 2003). Indeed, 5-HT 3 receptor antagonists have been used clinically for the treatment of chemotherapy-induced nausea/emesis and irritable bowel syndrome with diarrhoea (Minami et al., 1997;Kozlowski et al., 2000;Fukudo et al., 2014). We recently found that 5-HT 3 receptor antagonists such as ramosetron and ondansetron ameliorated intestinal injuries induced by the anticancer agent, 5-fluorouracil (5-FU), and the nonsteroidal anti-inflammatory drug, indomethacin (Kato et al., 2012;Yasuda et al., 2013). Several studies further showed that 5-HT 3 receptor antagonists reduced the severity of postoperative ileus and colitis (Mousavizadeh et al., 2009;Motavallian et al., 2013;Maehara et al., 2015). These findings suggest that endogenous 5-HT has pro-inflammatory effects that are mediated via 5-HT 3 ...